Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
81,149,970
-
Total 13F shares
-
3,257,983
-
Share change
-
+3,257,983
-
Total reported value
-
$39,909,852
-
Put/Call ratio
-
7.1%
-
Price per share
-
$12.25
-
Number of holders
-
27
-
Value change
-
+$39,909,852
-
Number of buys
-
27
Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) as of Q3 2023
As of 30 Sep 2023,
Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,257,983 shares.
The largest 10 holders included
Driehaus Capital Management LLC, Fairmount Funds Management LLC, Polar Capital Holdings Plc, WELLINGTON MANAGEMENT GROUP LLP, Affinity Asset Advisors, LLC, Logos Global Management LP, EcoR1 Capital, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, Rock Springs Capital Management LP, and COMMODORE CAPITAL LP.
This page lists
27
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.